+ Watch RPTP
on My Watchlist
Has a solid pipeline of products that should be advancing into phase 3 stage of FDA approval and beyond through the next 12 to 36 months. Most notable of all its products currently in phase 2 stage of development, is the drug Convivia. It is the only known drug currently in development and existence, that treats the "Asian Flush" symptoms associated with the consumption of alcohol by those who have the ALDH2 deficiency. There is a potentially huge market for this, as 40-50% of the East Asian populations suffers from this disorder alone. Chances are you know someone who suffers from this, evident by the appearence of red flush or blotchy areas to the face and neck area, and sometimes all over the body. Demand for this product could be very high as there are many medical(cancer risk) and social(public appearence) implications to having this disorder.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions